Inhibition of the B7-H3 immune checkpoint limits tumor growth by enhancing cytotoxic lymphocyte function

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer

Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989

Safety, activity, and immune correlates of anti–PD-1 antibody in cancer

Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628

Myeloid-derived-suppressor cells as regulators of the immune system

Gabrilovich, D. I., & Nagaraj, S. (2009) · Nature Reviews Immunology · doi:10.1038/nri2506 · Cited by 6,753

The B7–CD28 superfamily

Sharpe, A. H., & Freeman, G. J. (2002) · Nature reviews. Immunology · doi:10.1038/nri727 · Cited by 1,759

Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity

Curiel, T. J., Wei, S., Dong, H., Alvarez, X., Cheng, P., Mottram, P., Krzysiek, R., Knutson, K. L., Daniel, B., Zimmermann, M. C., et al. (2003) · Nature Medicine · doi:10.1038/nm863 · Cited by 1,314

B7-H3: A costimulatory molecule for T cell activation and IFN-γ production

Chapoval, A. I., Ni, J., Lau, J. S., Wilcox, R. A., Flies, D. B., Liu, D., Dong, H., Sica, G., Zhu, G., Tamada, K., et al. (2001) · Nature Immunology · doi:10.1038/85339 · Cited by 1,013

T Helper 17 Cells Promote Cytotoxic T Cell Activation in Tumor Immunity

Martín‐Orozco, N., Muranski, P. J., Chung, Y., Yang, X. O., Yamazaki, T., Lu, S., Hwu, P., Restifo, N. P., Overwijk, W. W., & Dong, C. (2009) · Immunity · doi:10.1016/j.immuni.2009.09.014 · Cited by 829

The B7 family member B7-H3 preferentially down-regulates T helper type 1–mediated immune responses

Suh, W.-K., Gajewska, B. U., Okada, H., Gronski, M. A., Bertram, E. M., Dawicki, W., Duncan, G. S., Bukczynski, J., Plyte, S., Elia, A., et al. (2003) · Nature Immunology · doi:10.1038/ni967 · Cited by 576

Antagonist Antibodies to PD-1 and B7-H1 (PD-L1) in the Treatment of Advanced Human Cancer—Response

Sznol, M., & Chen, L. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2234 · Cited by 532

PD ‐1 as a potential target in cancer therapy

McDermott, D. F., & Atkins, M. B. (2013) · Cancer Medicine · doi:10.1002/cam4.106 · Cited by 424

Cancer stemness, intratumoral heterogeneity, and immune response across cancers

Miranda, A., Hamilton, P. T., Zhang, A. W., Pattnaik, S., Becht, É., Mezheyeuski, A., Bruun, J., Micke, P., de Reyniès, A., & Nelson, B. H. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1818210116 · Cited by 581

Immunotherapy for osteosarcoma: Fundamental mechanism, rationale, and recent breakthroughs

Chen, C., Xie, L., Ren, T., Huang, Y., Xu, J. H., & Guo, W. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.12.024 · Cited by 587

Patient-derived xenograft models in cancer therapy: technologies and applications

Liu, Y., Wu, W., Cai, C., Zhang, H., Shen, H., & Han, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01419-2 · Cited by 533

Antitumor Responses in the Absence of Toxicity in Solid Tumors by Targeting B7-H3 via Chimeric Antigen Receptor T Cells

Du, H., Hirabayashi, K., Ahn, S., Kren, N. P., Montgomery, S. A., Wang, X., Tiruthani, K., Mirlekar, B., Michaud, D. E., Greene, K. G., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.01.002 · Cited by 483

MHC Class I Downregulation in Cancer: Underlying Mechanisms and Potential Targets for Cancer Immunotherapy

Cornel, A. M., Mimpen, I. L., & Nierkens, S. (2020) · Cancers · doi:10.3390/cancers12071760 · Cited by 501

PD-1 expression and clinical PD-1 blockade in B-cell lymphomas

Xu-Monette, Z. Y., Zhou, J., & Young, K. H. (2017) · Blood · doi:10.1182/blood-2017-07-740993 · Cited by 435

B7-H3: An Attractive Target for Antibody-based Immunotherapy

Kontos, F., Michelakos, T. P., Kurokawa, T., Sadagopan, A., Schwab, J. H., Ferrone, C. R., & Ferrone, S. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2584 · Cited by 407

CD276 expression enables squamous cell carcinoma stem cells to evade immune surveillance

Wang, C., Li, Y., Jia, L., Kim, J. K., Li, J., Deng, P., Zhang, W., Krebsbach, P. H., & Wang, C. (2021) · Cell stem cell · doi:10.1016/j.stem.2021.04.011 · Cited by 314

B7-H3/CD276: An Emerging Cancer Immunotherapy

Zhou, W.-T., & Jin, W. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.701006 · Cited by 303

Mechanisms of immune activation and regulation: lessons from melanoma

Kalaora, S., Nagler, A., Wargo, J. A., & Samuels, Y. (2022) · Nature reviews. Cancer · doi:10.1038/s41568-022-00442-9 · Cited by 252

Enhancing CAR-T cell efficacy in solid tumors by targeting the tumor microenvironment

Liu, G., Rui, W., Zhao, X., & Lin, X. (2021) · Cellular and Molecular Immunology · doi:10.1038/s41423-021-00655-2 · Cited by 244

Managing the immune microenvironment of osteosarcoma: the outlook for osteosarcoma treatment

Tian, H., Cao, J., Li, B., Nice, E. C., Mao, H., Zhang, Y., & Huang, C. (2023) · Bone Research · doi:10.1038/s41413-023-00246-z · Cited by 249

Exploiting innate immunity for cancer immunotherapy

Yi, M., Li, T., Niu, M., Mei, Q., Zhao, B., Chu, Q., Dai, Z., & Wu, K. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01885-w · Cited by 250

B7-H3 as a Novel CAR-T Therapeutic Target for Glioblastoma

Tang, X., Zhao, S., Zhang, Y., Wang, Y., Zhang, Z., Yang, M., Zhu, Y., Zhang, G., Guo, G. F., Tong, A., et al. (2019) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2019.07.002 · Cited by 197

Predictive biomarkers in gastric cancer

Röcken, C. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-022-04408-0 · Cited by 191

FUT8-mediated aberrant N-glycosylation of B7H3 suppresses the immune response in triple-negative breast cancer

Huang, Y., Zhang, H., Li, Z., Du, T., Chen, Y., Wang, Y., Ni, H.-H., Zhang, K., Mai, J., Hu, B., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22618-x · Cited by 188

A comprehensive review of immune checkpoint inhibitors for cancer treatment

Hossain, M. A. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113365 · Cited by 213

FcγR-Binding Is an Important Functional Attribute for Immune Checkpoint Antibodies in Cancer Immunotherapy

Chen, X., Song, X., Li, K., & Zhang, T. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00292 · Cited by 179

Natural-Killer-Derived Extracellular Vesicles: Immune Sensors and Interactors

Federici, C., Shahaj, E., Cecchetti, S., Camerini, S., Casella, M., Iessi, E., Camisaschi, C., Paolino, G., Calvieri, S., Ferro, S., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00262 · Cited by 166

Targeting tumor-associated macrophages as an antitumor strategy

Cheng, N., Bai, X., Shu, Y., Ahmad, O., & Shen, P. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114354 · Cited by 162

B7-H3 Suppresses Antitumor Immunity via the CCL2–CCR2–M2 Macrophage Axis and Contributes to Ovarian Cancer Progression

Miyamoto, T., Murakami, R., Hamanishi, J., Tanigaki, K., Hosoe, Y., Mise, N., Takamatsu, S., Mise, Y., Ukita, M., Taki, M., et al. (2021) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-21-0407 · Cited by 156

Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trial

Aggarwal, C., Prawira, A., Antonia, S. J., Rahma, O. E., Tolcher, A. W., Cohen, R. B., Lou, Y., Hauke, R. J., Vogelzang, N. J., Zandberg, D. P., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004424 · Cited by 153

Loss of BAP1 expression is associated with an immunosuppressive microenvironment in uveal melanoma, with implications for immunotherapy development

Figueiredo, C. R., Kalirai, H., Sacco, J. J., Azevedo, R., Duckworth, A. D., Slupsky, J. R., Coulson, J. M., & Coupland, S. E. (2020) · The Journal of Pathology · doi:10.1002/path.5384 · Cited by 151

Prognostic value of immune checkpoint molecules in breast cancer

Fang, J., Chen, F., Liu, D., Gu, F., Chen, Z., & Wang, Y.-Z. (2020) · Bioscience Reports · doi:10.1042/bsr20201054 · Cited by 139

B7-H3-Targeted CAR-T Cells Exhibit Potent Antitumor Effects on Hematologic and Solid Tumors

Zhang, Z., Jiang, C., Liu, Z., Yang, M., Tang, X., Wang, Y., Zheng, M., Huang, J., Zhong, K., Zhao, S., et al. (2020) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2020.03.019 · Cited by 134

Tumor-Associated Macrophages: A Potential Target for Cancer Therapy

Tan, Y., Wang, M., Zhang, Y., Ge, S., Zhong, F., Xia, G., & Sun, C. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.693517 · Cited by 138

Tumor-expressed B7-H3 mediates the inhibition of antitumor T-cell functions in ovarian cancer insensitive to PD-1 blockade therapy

Cai, D., Li, J., Liu, D., Hong, S., Qiao, Q., Sun, Q., Li, P., Lyu, N., Sun, T., Xie, S., et al. (2019) · Cellular and Molecular Immunology · doi:10.1038/s41423-019-0305-2 · Cited by 136

mTORC1 upregulates B7-H3/CD276 to inhibit antitumor T cells and drive tumor immune evasion

Liu, H.-J., Du, H., Khabibullin, D., Zarei, M., Wei, K., Freeman, G. J., Kwiatkowski, D. J., & Henske, E. P. (2023) · Nature Communications · doi:10.1038/s41467-023-36881-7 · Cited by 125

The B7-H3–Targeting Antibody–Drug Conjugate m276-SL-PBD Is Potently Effective Against Pediatric Cancer Preclinical Solid Tumor Models

Kendsersky, N. M., Lindsay, J., Kolb, E. A., Smith, M. A., Teicher, B. A., Erickson, S. W., Earley, E. J., Mosse, Y. P., Martinez, D., Pogoriler, J., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4221 · Cited by 120

Cancer exosomes and natural killer cells dysfunction: biological roles, clinical significance and implications for immunotherapy

Hosseini, R., Sarvnaz, H., Arabpour, M., Ramshe, S. M., Asef‐Kabiri, L., Yousefi, H., Akbari, M. E., & Eskandari, N. (2022) · Molecular Cancer · doi:10.1186/s12943-021-01492-7 · Cited by 119

Neoadjuvant enoblituzumab in localized prostate cancer: a single-arm, phase 2 trial

Shenderov, E., Marzo, A. M. D., Lotan, T. L., Wang, H., Chan, S., Lim, S. J., Ji, H., Allaf, M. E., Chapman, C. G., Moore, P. A., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02284-w · Cited by 119

B7-H3 Suppresses Antitumor Immunity via the CCL2–CCR2–M2 Macrophage Axis and Contributes to Ovarian Cancer Progression

Miyamoto, T., Murakami, R., Hamanishi, J., Tanigaki, K., Hosoe, Y., Mise, N., Takamatsu, S., Mise, Y., Ukita, M., Taki, M., et al. (2022) · Institutional Repositories DataBase (IRDB) · doi:10.14989/doctor.k23801 · Cited by 112

Cancer Immunotherapy: A Focus on the Regulation of Immune Checkpoints

Shi, T., Ma, Y., Yu, L., Jiang, J., Shen, S., Hou, Y., & Wang, T. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19051389 · Cited by 112

Autophagy protein ATG5 regulates CD36 expression and anti-tumor MHC class II antigen presentation in dendritic cells

Oh, D. S., & Lee, H. K. (2019) · Autophagy · doi:10.1080/15548627.2019.1596493 · Cited by 111

Expression of the inhibitory B7 family molecule VISTA in human colorectal carcinoma tumors

Xie, S., Huang, J., Qiao, Q., Zang, W., Hong, S., Tan, H., Dong, C., Yang, Z., & Ni, L. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2227-8 · Cited by 105

B7-H3 as a Therapeutic Target in Advanced Prostate Cancer

Guo, C. W., Figueiredo, I., Gürel, B., Neeb, A., Seed, G., Crespo, M., Carreira, S., Rekowski, J., Buroni, L., Welti, J. C., et al. (2022) · European Urology · doi:10.1016/j.eururo.2022.09.004 · Cited by 113

Engineering MMP-2 Activated Nanoparticles Carrying B7-H3 Bispecific Antibodies for Ferroptosis-Enhanced Glioblastoma Immunotherapy

Fan, R., Chen, C., Mu, M., Chuan, D., Liu, H., Hou, H., Huang, J., Tong, A., Guo, G. F., & Xu, J. (2023) · ACS Nano · doi:10.1021/acsnano.2c12217 · Cited by 104

Genetic and clinical characterization of B7‐H3 (CD276) expression and epigenetic regulation in diffuse brain glioma

Wang, Z., Wang, Z., Zhang, C., Liu, X., Li, G., Liu, S., Sun, L., Liang, J., Hu, H., Liu, Y., et al. (2018) · Cancer Science · doi:10.1111/cas.13744 · Cited by 101

Targeting B7-H3 via chimeric antigen receptor T cells and bispecific killer cell engagers augments antitumor response of cytotoxic lymphocytes

Liu, J., Yang, S., Cao, B., Zhou, G., Zhang, F., Wang, Y., Wang, R., Zhu, L., Meng, Y., Hu, C., et al. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-01024-8 · Cited by 96

The importance of immune checkpoints in immune monitoring: A future paradigm shift in the treatment of cancer

Alemohammad, H., Najafzadeh, B., Asadzadeh, Z., Baghbanzadeh, A., Ghorbaninezhad, F., Najafzadeh, A., Safarpour, H., Bernardini, R., Brunetti, O., Sonnessa, M., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112516 · Cited by 92

Beyond CTLA-4 and PD-1 Inhibition: Novel Immune Checkpoint Molecules for Melanoma Treatment

Ziogas, D. C., Theocharopoulos, C., Lialios, P., Foteinou, D., Koumprentziotis, I., Xynos, G., & Gogas, H. J. (2023) · Cancers · doi:10.3390/cancers15102718 · Cited by 95

Large-scale analysis reveals the specific clinical and immune features of B7-H3 in glioma

Zhang, C., Zhang, Z., Li, F., Shen, Z., Qiao, Y., Li, L., Liu, S., Song, M., Zhao, X., Ren, F., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1461304 · Cited by 91

Preclinical Evaluation of B7-H3–specific Chimeric Antigen Receptor T Cells for the Treatment of Acute Myeloid Leukemia

Lichtman, E. I., Du, H., Shou, P., Song, F., Suzuki, K., Ahn, S., Li, G., Ferrone, S., Su, L., Savoldo, B., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2540 · Cited by 87

Transcriptomic and immunophenotypic profiling reveals molecular and immunological hallmarks of colorectal cancer tumourigenesis

Roelands, J. P., van der Ploeg, M., Ijsselsteijn, M. E., Dang, H., Boonstra, J. J., Hardwick, J. C. H., Hawinkels, L. J. A. C., Morreau, H. M., & de Miranda, N. F. C. C. (2022) · Gut · doi:10.1136/gutjnl-2022-327608 · Cited by 87

B7-H3 inhibits the IFN-γ-dependent cytotoxicity of Vγ9Vδ2 T cells against colon cancer cells

Lu, H., Shi, T., Wang, M., Li, X., Gu, Y., Zhang, X., Zhang, G., & Chen, W. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1748991 · Cited by 82

B7-H3 promotes multiple myeloma cell survival and proliferation by ROS-dependent activation of Src/STAT3 and c-Cbl-mediated degradation of SOCS3

Lin, L., Cao, L., Liu, Y., Wang, K., Zhang, X., Qin, X., Zhao, D., Hao, J., Chang, Y., Huang, X., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0331-6 · Cited by 80

B7-H3 Immune Checkpoint Protein in Human Cancer

Karlsen, K. F., Fodstad, Ø., & Nunes‐Xavier, C. E. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867326666190517115515 · Cited by 80

CAR‐T cell therapy for lung cancer: Potential and perspective

Chen, L., Chen, F., Li, J., Pu, Y., Yang, C., Wang, Y., Lei, Y., & Huang, Y. (2022) · Thoracic Cancer · doi:10.1111/1759-7714.14375 · Cited by 78

Targeting B7-H3 Immune Checkpoint With Chimeric Antigen Receptor-Engineered Natural Killer Cells Exhibits Potent Cytotoxicity Against Non-Small Cell Lung Cancer

Yang, S., Cao, B., Zhou, G., Zhu, L., Wang, L., Zhang, L., Kwok, H. F., Zhang, Z., & Zhao, Q. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.01089 · Cited by 76

B7-H3 Regulates Glioma Growth and Cell Invasion Through a JAK2/STAT3/Slug-Dependent Signaling Pathway

Zhong, C., Tao, B., Chen, Y., Guo, Z., Yang, X., Peng, L., Xia, X., & Chen, L. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s237841 · Cited by 76

Therapeutic targeting of TGF-β in cancer: hacking a master switch of immune suppression

van den Bulk, J., de Miranda, N. F. C. C., & ten Dijke, P. (2021) · Clinical Science · doi:10.1042/cs20201236 · Cited by 78

High-resolution structural genomics reveals new therapeutic vulnerabilities in glioblastomaPreprint

Johnston, M. J. G., Nikolić, A., Ninkovic, N., Guilhamon, P., Cavalli, F. M. G., Seaman, S., Zemp, F. J., Lee, J., Abdelkareem, A. O., Ellestad, K. I., et al. (2019) · Genome Research · doi:10.1101/gr.246520.118 · Cited by 68

CD276 regulates the immune escape of esophageal squamous cell carcinoma through CXCL1–CXCR2 induced NETs

Xiong, G., Chen, Z., Liu, Q., Peng, F., Zhang, C., Cheng, M., Ling, R., Chen, S., Liang, Y., Chen, D., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-008662 · Cited by 74

FN1 overexpression is correlated with unfavorable prognosis and immune infiltrates in breast cancer

Zhang, X., Luo, J.-H., & Wu, L. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.913659 · Cited by 72

Natural Killer Cells: Angels and Devils for Immunotherapy

Martín-Antonio, B., Suñé, G., Pérez-Amill, L., Castellà, M., & Urbano-Ispizúa, Á. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18091868 · Cited by 73

Monocyte-derived APCs are central to the response of PD1 checkpoint blockade and provide a therapeutic target for combination therapy

Schetters, S. T. T., Rodríguez, E., Kruijssen, L. J. W., Crommentuijn, M. H. W., Boon, L., den Bossche, J. V., den Haan, J. M. M., & van Kooyk, Y. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000588 · Cited by 79

B7-H3 augments the pro-angiogenic function of tumor-associated macrophages and acts as a novel adjuvant target for triple-negative breast cancer therapy

Cheng, N., Bei, Y., Song, Y., Zhang, W., Xu, L., Zhang, W., Yang, N., Bai, X., Shu, Y., & Shen, P. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114298 · Cited by 72

Immune infiltration profiling in gastric cancer and their clinical implications

Ren, F., Zhao, Q., Zhao, M., Shaogong, Z., Liu, B., Bukhari, I., Zhang, K., Wu, W., Fu, Y., Yu, Y., et al. (2021) · Cancer Science · doi:10.1111/cas.15057 · Cited by 73

Inhibitory Receptors and Immune Checkpoints Regulating Natural Killer Cell Responses to Cancer

Buckle, I., & Guillerey, C. (2021) · Cancers · doi:10.3390/cancers13174263 · Cited by 74

Effects of B7-H3 expression on tumour-infiltrating immune cells and clinicopathological characteristics in non–small-cell lung cancer

Yim, J., Koh, J., Kim, S., Song, S. G., Ahn, H. K., Kim, Y. A., Jeon, Y. K., & Chung, D. H. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.03.033 · Cited by 67

Microbiota-dependent activation of the myeloid calcineurin-NFAT pathway inhibits B7H3- and B7H4-dependent anti-tumor immunity in colorectal cancer

Peuker, K., Strigli, A., Tauriello, D. V. F., Hendricks, A., Schönfels, W. V., Burmeister, G., Brosch, M., Herrmann, A., Krüger, S., Nitsche, J., et al. (2022) · Immunity · doi:10.1016/j.immuni.2022.03.008 · Cited by 68

Development of pharmacological immunoregulatory anti-cancer therapeutics: current mechanistic studies and clinical opportunities

Yin, N., Li, X., Zhang, X., Xue, S., Cao, Y., Niedermann, G., Lu, Y., & Xue, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01826-z · Cited by 74

The role of B7-H3 in tumors and its potential in clinical application

Feng, R.-R., Chen, Y., Liu, Y., Zhou, Q., & Zhang, W. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.108153 · Cited by 61

CAR T Cell Therapy for Pediatric Brain Tumors

Patterson, J. D., Henson, J. C., Breese, R. O., Bielamowicz, K., & Rodriguez, A. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01582 · Cited by 59

Glycosylation of Immune Receptors in Cancer

Sun, R., Kim, A. M. J., & Lim, S. (2021) · Cells · doi:10.3390/cells10051100 · Cited by 58

Inhibitor of glutamine metabolism V9302 promotes ROS-induced autophagic degradation of B7H3 to enhance antitumor immunity

Li, Q., Zhong, X., Yao, W., Yu, J., Wang, C., Li, Z., Lai, S., Qu, F., Fu, X., Huang, X., et al. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.101753 · Cited by 58

B7-H3 immunoregulatory roles in cancer

Mortezaee, K. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114890 · Cited by 57

B7-H3×4-1BB bispecific antibody augments antitumor immunity by enhancing terminally differentiated CD8 + tumor-infiltrating lymphocytes

You, G., Lee, Y., Kang, Y., Park, H. W., Park, K., Kim, H., Kim, Y., Kim, S., Kim, J., Moon, D., et al. (2021) · Science Advances · doi:10.1126/sciadv.aax3160 · Cited by 57

VSIG4+ tumor-associated macrophages mediate neutrophil infiltration and impair antigen-specific immunity in aggressive cancers through epigenetic regulation of SPP1

Pan, Z., Chen, J., Xu, T. C., Cai, A., Han, B., Li, Y., Fang, Z., Yu, D., Wang, S., Zhou, J., et al. (2025) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-025-03303-z · Cited by 56

PLA2G4A promotes right-sided colorectal cancer progression by inducing CD39+γδ Treg polarization

Zhan, Y., Zheng, L., Liu, J., Hu, D., Wang, J., Liu, K., Guo, J., Zhang, T., & Kong, D. (2021) · JCI Insight · doi:10.1172/jci.insight.148028 · Cited by 53

Lipid Nanoparticle Delivery System for mRNA Encoding B7H3‐redirected Bispecific Antibody Displays Potent Antitumor Effects on Malignant Tumors

Huang, C., Duan, X., Wang, J., Tian, Q., Ren, Y., Chen, K., Zhang, Z., Li, Y., Feng, Y., Zhong, K., et al. (2022) · Advanced Science · doi:10.1002/advs.202205532 · Cited by 56

B7-H3 targeted CAR-T cells show highly efficient anti-tumor function against osteosarcoma both in vitro and in vivo

Zhang, Q., Zhang, Z., Liu, G., Li, D., Gu, Z., Zhang, L., Pan, Y., Cui, X., Wang, L., Liu, G., et al. (2022) · BMC Cancer · doi:10.1186/s12885-022-10229-8 · Cited by 51

Identification of m6A methyltransferase-related lncRNA signature for predicting immunotherapy and prognosis in patients with hepatocellular carcinoma

Li, L., Xie, R., & Lu, G. (2021) · Bioscience Reports · doi:10.1042/bsr20210760 · Cited by 51

Pediatric versus adult high grade glioma: Immunotherapeutic and genomic considerations

Aggarwal, P., Luo, W., Pehlivan, K. C., Hoang, H., Rajappa, P., Cripe, T. P., Cassady, K. A., Lee, D. A., & Cairo, M. S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1038096 · Cited by 56

B7-H3 immune checkpoint expression is a poor prognostic factor in colorectal carcinoma

Lu, Z., Zhao, Z., Cheng, P., Huang, F., Guan, X., Zhang, M., Chen, H., Liu, Z., Jiang, Z., Zheng, Z., et al. (2020) · Modern Pathology · doi:10.1038/s41379-020-0587-z · Cited by 49

Immune Checkpoints in Cancers: From Signaling to the Clinic

Pisibon, C., Ouertani, A., Bertolotto, C., Ballotti, R., & Chéli, Y. (2021) · Cancers · doi:10.3390/cancers13184573 · Cited by 51

Over-Expression and Prognostic Significance of FN1, Correlating With Immune Infiltrates in Thyroid Cancer

Geng, Q., Huang, T., Li, L., Shen, Z., Xue, W., & Zhao, J. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2021.812278 · Cited by 48

B7-H3 in Brain Malignancies: Immunology and Immunotherapy

Guo, X., Chang, M., Wang, Y., Xing, B., & Ma, W. (2023) · International Journal of Biological Sciences · doi:10.7150/ijbs.85813 · Cited by 55

The Role of TIM-3 in Hepatocellular Carcinoma: A Promising Target for Immunotherapy?

Ganjalıkhani-Hakemi, M., Jafarinia, M., Azizi, M., Rezaeepoor, M., Isayev, O., & Bazhin, A. V. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.601661 · Cited by 53

LINC01123 promotes immune escape by sponging miR-214-3p to regulate B7–H3 in head and neck squamous-cell carcinoma

Li, H., Yang, Z., Yang, X., Zhang, F., Wang, J., Wu, Z., Wanyan, C., Meng, Q., Gao, W., Yang, X., et al. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-04542-0 · Cited by 45

Novel bispecific antibody-drug conjugate targeting PD-L1 and B7-H3 enhances antitumor efficacy and promotes immune-mediated antitumor responses

Dong, Y., Zhang, Z., Luan, S., Zheng, M., Wang, Z., Chen, Y., Chen, X., Tong, A., & Yang, H. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-009710 · Cited by 49

Transcriptome analysis of desmoplastic small round cell tumors identifies actionable therapeutic targets: a report from the Children’s Oncology Group

Hingorani, P., Dinu, V., Zhang, X., Lei, H., Shern, J. F., Park, J. H., Steel, J., Rauf, F., Parham, D. M., Gastier, J. M., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-69015-w · Cited by 46

MYCN Drives a Tumor Immunosuppressive Environment Which Impacts Survival in Neuroblastoma

Raieli, S., Renzo, D. D., Lampis, S., Amadesi, C., Montemurro, L., Pession, A., Hrelia, P., Fischer, M., & Tonelli, R. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.625207 · Cited by 45

To kill a cancer: Targeting the immune inhibitory checkpoint molecule, B7-H3

Kanchan, R. K., Doss, D., Κhan, P., Nasser, M. W., & Mahapatra, S. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2022.188783 · Cited by 44

Interleukin-17D Promotes Pathogenicity During Infection by Suppressing CD8 T Cell Activity

Lee, Y., Clinton, J., Yao, C., & Chang, S. H. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01172 · Cited by 42

MicroRNA-326 attenuates immune escape and prevents metastasis in lung adenocarcinoma by targeting PD-L1 and B7-H3

Shao, L., He, Q., Wang, J., He, F., Lin, S., Wu, L., Gao, Y., Ma, W., Dong, J., Yang, X., et al. (2021) · Cell Death Discovery · doi:10.1038/s41420-021-00527-8 · Cited by 43

B7-H3 targeted antibody-based immunotherapy of malignant diseases

Michelakos, T. P., Kontos, F., Barakat, O., Maggs, L., Schwab, J. H., Ferrone, C. R., & Ferrone, S. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2021.1862791 · Cited by 41

Expression of Programmed Cell Death-Ligands in Hepatocellular Carcinoma: Correlation With Immune Microenvironment and Survival Outcomes

Liao, H., Chen, W., Dai, Y., Richardson, J. J., Guo, J., Yuan, K., Zeng, Y., & Xie, K. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00883 · Cited by 41

Potential Therapeutic Targets of B7 Family in Colorectal Cancer

Wang, C., Feng, H., Cheng, X., Liu, K., Cai, D., & Zhao, R. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00681 · Cited by 42

Approaches to Enhance Natural Killer Cell-Based Immunotherapy for Pediatric Solid Tumors

Quamine, A. E., Olsen, M. R., Cho, M. M., & Capitini, C. M. (2021) · Cancers · doi:10.3390/cancers13112796 · Cited by 39

Surfaceome Profiling of Rhabdomyosarcoma Reveals B7-H3 as a Mediator of Immune Evasion

Lavoie, R. R., Gargollo, P. C., Ahmed, M. E., Kim, Y., Baer, E., Phelps, D. A., Charlesworth, C. M., Madden, B. J., Wang, L., Houghton, P. J., et al. (2021) · Cancers · doi:10.3390/cancers13184528 · Cited by 38

Regulation of autophagy fires up the cold tumor microenvironment to improve cancer immunotherapy

Jin, Z., Sun, X., Wang, Y., Zhou, C., Yang, H., & Zhou, S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1018903 · Cited by 39

B7-H3 Specific CAR T Cells for the Naturally Occurring, Spontaneous Canine Sarcoma Model

Zhang, S., Black, R. G., Kohli, K., Hayes, B. J., Miller, C., Koehne, A. L., Schroeder, B., Abrams, K., Schulte, B. C., Alexiev, B. A., et al. (2022) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-21-0726 · Cited by 39

EBV-Upregulated B7-H3 Inhibits NK cell–Mediated Antitumor Function and Contributes to Nasopharyngeal Carcinoma Progression

Chen, H., Duan, X., Deng, X., Huang, Y., Zhou, X., Zhang, S., Zhang, X., Liu, P., Yang, C., Liu, G., et al. (2023) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-22-0374 · Cited by 37

Tracers for non-invasive radionuclide imaging of immune checkpoint expression in cancer

Wierstra, P. J., Sandker, G. W., Aarntzen, E. H. J. G., Gotthardt, M., Adema, G. J., Bussink, J., Raavé, R., & Heskamp, S. (2019) · EJNMMI Radiopharmacy and Chemistry · doi:10.1186/s41181-019-0078-z · Cited by 39

Efficacy of B7-H3-Redirected BiTE and CAR-T Immunotherapies Against Extranodal Nasal Natural Killer/T Cell Lymphoma

Zheng, M., Yu, L., Hu, J., Zhang, Z., Wang, H., Lu, D., Tang, X., Huang, J., Zhong, K., Wang, Z., et al. (2020) · Translational Oncology · doi:10.1016/j.tranon.2020.100770 · Cited by 37

B7-H3/CD276 and small-cell lung cancer: What's new?

Fabrizio, F. P., Muscarella, L. A., & Rossi, A. (2023) · Translational Oncology · doi:10.1016/j.tranon.2023.101801 · Cited by 37

A Comprehensive Analysis of Baseline Clinical Characteristics and Biomarkers Associated with Outcome in Advanced Melanoma Patients Treated with Pembrolizumab

Awada, G., Jansen, Y. J. L., Schwarze, J. K., Tijtgat, J., Hellinckx, L., Gondry, O., Vermeulen, S., Warren, S. E., Schats, K., van Dam, P., et al. (2021) · Cancers · doi:10.3390/cancers13020168 · Cited by 36

Update of early phase clinical trials in cancer immunotherapy

Lee, D. H. (2021) · BMB Reports · doi:10.5483/bmbrep.2021.54.1.242 · Cited by 37

Epigenetic Regulation of Immunotherapy Response in Triple-Negative Breast Cancer

Llinàs‐Arias, P., Íñiguez-Muñoz, S., McCann, K. E., Voorwerk, L., Orozco, J. I. J., Ensenyat-Méndez, M., Sesé, B., DiNome, M. L., & Marzese, D. M. (2021) · Cancers · doi:10.3390/cancers13164139 · Cited by 36

Abstract 494: Novel human B7-H3 knock-in mice demonstrate efficacy of anti-B7-H3 immunotherapy in vivo

Zhao, L., Li, H., Liu, Y., Yu, Z.-X., & Lin, E. (2021) · Cancer Research · doi:10.1158/1538-7445.am2021-494

Inhibition of the B7-H3 immune checkpoint limits hepatocellular carcinoma progression by enhancing T lymphocyte-mediated immune cytotoxicity in vitro and in vivo

Zhou, Z., Yu, X., Chen, Y., Tan, X., Liu, W., Hua, W., Chen, L., & Zhang, W. (2022) · Clinical & Translational Oncology · doi:10.1007/s12094-022-03013-4 · Cited by 12

New checkpoints in cancer immunotherapy

Ni, L., & Dong, C. (2017) · Immunological Reviews · doi:10.1111/imr.12524 · Cited by 143

To kill a cancer: Targeting the immune inhibitory checkpoint molecule, B7-H3

Kanchan, R. K., Doss, D., Κhan, P., Nasser, M. W., & Mahapatra, S. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2022.188783 · Cited by 44

Mouse B7-H3 induces antitumor immunity

Sun, X., Vale, M., Leung, E. Y., Kanwar, J. R., Gupta, R., & Krissansen, G. W. (2003) · Gene Therapy · doi:10.1038/sj.gt.3302070 · Cited by 131